Despite the high rate of complete remission for patients with ALL, a majority of patients will develop relapsed or refractory disease. Recent advances expanding available therapeutic options could change the standard of care for these patients.

Case managers and medical directors need to have wide-ranging knowledge about how solid tumors are managed so that they can help patients with solid tumors coordinate their care among different specialists (e.g., diagnostic radiology, medical oncology, palliative care).

Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options.

As multidisciplinary cancer care becomes increasingly common, it is important for all members of the care team to understand the basics of cancer biology, diagnosis, and treatment to best care for their patients.